EnabaLink^® Drug Discovery Engine

To better understand the chemokine system and to accelerate the identification of small molecule lead compounds, we have developed a suite of proprietary technologies, known as the EnabaLink® drug discovery engine. We believe that this platform provides us with a one-of-a-kind advantage in the rapid identification of highly specific drug candidates. It includes the following platform elements developed by the company:

• Comprehensive Map of the Chemokine Network

We have developed a thorough functional genomic map of the chemokine system which assists us in our understanding of the role of a given chemokine receptor in the system as well as its likely effect on the migration of inflammatory cells in a given inflammatory disease state.

• Reverse Activation of Migration (RAM) Assays and Screening Technology

With this understanding of the chemokine network, we can apply our advanced screening methodologies, including a purpose-built high-throughput robotic screening technology, known as the Reverse Activation of Migration, or RAM, Assay, to identify small molecule antagonists for the chemokine receptor most closely associated with a specific disease. The RAM Assay is designed to markedly reduce or eliminate non-specific inhibitors and toxic inhibitors of cell migration, resulting in highly specific lead candidates. This technology allows us to screen against targets that are not accessible with traditional technologies, providing us with what we believe to be a competitive advantage in drug discovery.

ChemoCentryx has utilized the EnabaLink drug discovery engine for the identification and optimization of each of its clinical and pre-clinical drug candidates. We continue to apply these proprietary research tools in our early-stage drug discovery efforts and to leverage our expertise and proprietary technologies in order to continue discovering and developing a broad pipeline of novel chemokine-based therapeutics.